700 SAGINAW DR, REDWOOD CITY, CA
Other Events
Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Submission of Matters to a Vote of Security Holders
Enters Into $2 Billion Flexible Funding Agreement to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
Changes in Board, Management or Compensation
Earnings Release
Annual Report to Security Holders
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Certificate
Additional Proxy Materials
Definitive Proxy Statement
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities